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ABSTRACT
Background: Antibiotic resistance is a growing
problem worldwide, but communicating this challenge
to policymakers and non-experts is complicated by the
multiplicity of bacterial pathogens and the distinct
classes of antibiotics used to treat them. It is
difﬁcult, even for experts aware of the
pharmacodynamics of antibiotics, to infer the
seriousness of resistance without information on how
commonly the antibiotic is being used and whether
alternative antibiotics are available. Difﬁculty in
aggregating resistance to multiple drugs to assess
trends poses a further challenge to quantifying and
communicating changes in resistance over time and
across locations.
Methods: We developed a method for aggregating
bacterial resistance to multiple antibiotics, creating an
index comparable to the composite economic indices
that measure consumer prices and stock market
values. The resulting drug resistance index (DRI) and
various subindices show antibiotic resistance and
consumption trends in the USA but can be applied at
any geographical level.
Findings: The DRI based on use patterns in 1999 for
Escherichia coli rose from 0.25 (95% CI 0.23 to 0.26)
to 0.30 (95% CI 0.29 to 0.32) between 1999 and 2006.
However, the adaptive DRI, which includes treatment
of baseline resistant strains with alternative agents,
climbed from 0.25 to 0.27 (95% CI 0.25 to 0.28)
during that period. In contrast, both the static-use and
the adaptive DRIs for Acinetobacter spp. rose from
0.41 (95% CI 0.4 to 0.42) to 0.48 (95% CI 0.46 to
0.49) between 1999 and 2006.
Interpretation: Divergence between the static-use
and the adaptive-use DRIs for E coli reﬂects the ability
of physicians to adapt to increasing resistance.
However, antibiotic use patterns did not change
much in response to growing resistance to
Acinetobacter spp. because physicians were unable
to adapt; new drugs for Acinetobacter spp. are
therefore needed. Composite indices that aggregate
resistance to various drugs can be useful for
assessing changes in drug resistance across time
and space.
INTRODUCTION
That antibiotics are losing effectiveness
around the world is by now clear not just to
the medical profession but also to those
following media stories on the rise of
‘superbugs’. However, efforts to effectively
communicate the challenge of antibiotic
resistance to the lay public and policymakers
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ARTICLE SUMMARY
Article focus
- The difﬁculty in aggregating resistance to
multiple drugs to assess trends poses a
challenge to quantifying and communicating
changes in drug resistance over time and
across locations.
- We developed a method for aggregating bacterial
resistance to multiple antibiotics, creating a drug
resistance index comparable to the composite
economic indices that measure consumer prices
and stock market values.
Key messages
- Composite indices that aggregate resistance to
various drugs can be useful for assessing
changes in drug resistance across time and
space.
- Divergence between the static-use and the
adaptive-use DRIs for Escherichia coli reﬂects
the ability of physicians to adapt to increasing
resistance. Antibiotic use patterns did not change
much in response to growing resistance to
Acinetobacter spp., indicating the limited treat-
ment options physicians are left with and
the need to develop new drugs against this
pathogen.
Strengths and limitations
- The resistance index takes a ﬁrst important step
towards making trends in resistance intelligible
to non-experts and useful to experts.
- Gathering accurate data on antibiotic sales is
particularly challenging in countries with a large
informal pharmaceutical sector. However, our
model only requires consistency in trends in
antibiotic consumption and it is likely to be
a consistent measure of trends unless there is
systematic time-variant bias in measuring
components of the index.
- We demonstrate the drug resistance index using
US data, but alternative applications include all
other geographical levels, or the scale of
individual facilities, where data on both resis-
tance and antibiotic use are likely to be available.
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Open Access Researchhave been somewhat unsuccessful. Despite increased
attention in the USA and Europe to the resistance
problem, there has been little progress in allocating
ﬁnancial resources either to conserve the effectiveness of
existing drugs or to incentivise the development of
new antibiotics. As one journal editor put it, ‘it is
time that antibiotic resistance became an issue of
popular concern rather than the interest of a few
experts’.
1 Several reasons explain why this has not
happened.
First, policymakers are largely unfamiliar with the
scientiﬁc names of pathogens. To a policymaker, that
susceptibility of Streptococcus pneumoniae to penicillin is
40% may carry little meaning.
Second, data on the resistance of a pathogen to one or
more drugs may be viewed out of context if substitutes to
treat the infection exist. In the USA, growing resistance
of Escherichia coli to trimethoprimesulfamethoxazole has
been accompanied by a reduction in the proportion of
patients treated with that drug. How should we view
the increase in resistance to drugs that are declining in
use? Is resistance as critical when we have near-substi-
tutes that clinicians can deploy, such as imipenem in the
case of E coli? If doctors use injectable cephalosporins
a hundred times more often than they do penicillin to
treat invasive infections caused by S pneumoniae,
shouldn’t resistance to those cephalosporins carry more
weight than resistance to penicillin?
Third, resistance goes up in some years and down in
others, as seen in resistance of Staphylococcus aureus to
oxacillin (MRSA) in several European countries
2 and
Acinetobacter spp. to ciproﬂoxacin. In aggregate, has
resistance to the antibiotics used most commonly to treat
infections caused by these two pathogens increased or
decreased over time?
Fourth is a problem speciﬁc to bacterial pathogens:
antibiotic resistance affects not a single disease, like
HIV, TB or malaria, but rather a set of syndromes and
infections caused by different bacteria. A policymaker
may understand that drugs to treat HIV/AIDS are
failing but be unable to grasp the complexity of
bacterial resistance. Therefore, information on suscep-
tibility to a single pathogen and a single antibiotic
cannot inform priority setting and allocation of health
resources.
Here, we propose a drug resistance index (DRI) that
can be used to communicate gaps in antibiotic effec-
tiveness to non-experts. This index is based on economic
metrics, like the consumer price indices or stock market
indices, which are used in nearly every country. The
purpose of these indices is simpledto quantify the
average cost of purchasing a basic basket of goods and
services deemed essential to living (in the case of price
indices) or the average price of a basket of shares being
traded (in the case of stock market indices). In our case,
the metric should communicate the average effective-
ness of the set of antibiotics that are used to treat a given
bacterial infection.
METHODS AND DATA
Drug resistance indices
There are ﬁve attributes desirable in a DRI. First, the
DRI should be comparable across time and location
so that it can be used to measure changes in drug
effectiveness in a single country over time as well as to
compare effectiveness across countries. Second, the DRI
should be calculable with minimal data but be able to
incorporate more information to improve precision
when additional data become available. Third, the DRI
should be simple enough that policymakers, the lay
public and non-infectious disease medical practitioners
can comprehend gaps in drug effectiveness, affordability
and accessibility. Fourth, resistance of a pathogen to
a speciﬁc drug should be weighted by the extent to
which that drug is used for treating the pathogen, in
much the same way that an inﬂation index weights the
price of different commodities by the average share of
income devoted to them. A change in the price of salt
should affect the consumer price index by a smaller
amount than an equal percentage change in the price of
gasoline, which is used in greater quantities by the
average household.
Finally, the resistance index should be sensitive to
changes in the types of drugs being used. The ﬁrst
description of high-level resistance to ampicillin
(b-lactamase production) in Haemophilus inﬂuenzae
3 was
sufﬁcient to change empiric meningitis treatment
from penicillin or ampicillin to the extended-spectrum
cephalosporins in the developed world. Despite wide-
spread b-lactamase-producing H inﬂuenzae and peni-
cillin-resistant pneumococci, this shift has only recently
begun in developing countries, as the extended-spec-
trum cephalosporins come off patent and become
affordable. The adaptive index for treatment of menin-
gitis remains low in the developed world and is much
higher in developing countries where alternative therapy
thus remains limited in its availability.
Data
Computing the DRI requires data on bacterial suscepti-
bility and antibiotic use. The scale at which these data
are needed depends on the scale at which the resistance
index is being computeddas low as the level of an
individual healthcare facility or as high as a country or
region. Ideally, resistance data are representative at the
level for which the index is being computed. The
weighting data are estimates of the shares of the
different types of antibiotics as a proportion of treat-
ments indicated for pathogens covered by the index.
These weights are based on antibiotic use data obtained
from hospital pharmacies and commercial sources, such
as IMS Health. In places where detailed antibiotic use
data are not available, structured expert elicitation and
other such methods can be used to elicit information on
the proportions of antibiotics used to treat speciﬁc
infections.
4 For resistance indices related to infections
deﬁned by a speciﬁc anatomical site (pneumonia,
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Communicating trends in resistance using a drug resistance indexmeningitis, sepsis, urinary tract infection (UTI), etc),
additional data are needed to weight each pathogen
based on the etiologic fraction, that is, the proportion of
infections they cause.
Role of the funding source
The institutions that supported this work had no role
in study conception, data collection, analysis and
interpretation, and writing of the manuscript. All
authors had full access to the data. All authors had
the ﬁnal responsibility for the decision to submit for
publication.
Example index
The DRI measures changes through time in the
proportion of disease-causing pathogens that are resis-
tant to the antibiotics commonly used to treat them. For
the purpose of exposition, we have constructed a DRI for
two pathogens, E coli and Acinetobacter spp., using
national US data on the proportion of isolates tested that
are resistant and antibiotic consumption. The annual
percentage change in the DRI is a measure of the rate of
depletion of antibiotic effectiveness.
Since antibiotic use may change over time in response
to changing levels of antibiotic resistance, we compare
trends in the index with the counterfactual case, where
antibiotic use remains ﬁxed to a baseline year. A static-
use DRI allows assessment of the extent to which drug
use has adapted in response to resistance and the
burden that this resistance would have caused if antibi-
otic use patterns had not changed:
Ri;fixed use ¼ +
k
r
t
ikq
0
ik;
where rt
ik is the proportion of resistance among organism
i to drug k at time t and q0
ik is the frequency of drug k
used to treat organism i in the base year of the analysis.
Changing antibiotic use patterns over time may miti-
gate the burden of antibiotic resistance. To incorporate
changing trends in antibiotic use, we also construct an
adaptive version of the DRI; it aggregates the frequency
with which infections from a particular pathogen are
resistant to antibiotic treatment and may be estimated as
follows:
Ri ¼ +
k
r
t
ikq
t
ik;
where rt
ik is the proportion of resistance among
organism i to drug k at time t and qt
ik is the frequency of
drug k used to treat organism i at time t.
Implementing the DRI using US data
Prevalence of resistance rt
ik was calculated using The
Surveillance Network Database, USA (Euroﬁns Medinet,
Herndon, Virginia, USA). The Surveillance Network is
a nationally and regionally representative database of
bacterial species identiﬁcation and antibiotic suscepti-
bility results gathered from 300 US hospitals.
5 Frequency
of drug use q0
ik for the USA was obtained from IMS
Health Xponent database. Xponent tracks >70% of all
outpatient prescriptions in the USA using transaction
records at retail pharmacies and uses a patented
projection methodology to represent 100% coverage of
all prescription activity.
CIs for the indices were derived using a non-para-
metric bootstrap method with n¼10000 observations
drawn at random from each of the itemised data sets of
antibiotic prescriptions and individual susceptibility tests
and replicated m¼1000 times. Statistical analysis was
performed using STATA V.11 (Stata Corporation) and
R V.2.13.1 (Free Software Foundation Inc., Boston,
Massachusetts, USA).
Figure 1A,B shows that resistance of E coli and Acine-
tobacter spp. inpatient and outpatient isolates in the USA
increased between 1999 and 2006. Rates of increase were
remarkable for Acinetobacter spp. resistant to carbape-
nems and ﬂuoroquinolones, as well as for E coli resistant
to ﬂuoroquinolones, trimethoprimesulfamethoxazole
(TMP-SMX) and aminopenicillins. Figure 2A,B shows
prescribing proportions for antibiotics that were
featured in The Surveillance Network database of
susceptibility tests for Acinetobacter spp. and E coli and are
commonly used to treat gram-negative infections. For E
coli, usage patterns have shifted towards increased ﬂuo-
roquinolone and later generation cephalosporin use in
lieu of less expensive alternatives, such as amino-
penicillins and TMP-SMX.
Static-use and adaptive-use DRIs are shown in ﬁgure 3.
For Acinetobacter spp., the static-use DRI increased by
17%, from 0.41 to 0.48, while for E coli, the static-use DRI
increased from 0.25 to 0.30. The results show that for E
coli, the static-use DRI exceeds the adaptive-use DRI for
all years, which increases from 0.25 to 0.27 between 1999
and 2006. This rate of increase is lower than for the
static-use DRI with a statistically signiﬁcant difference for
2006, indicating that clinicians were able to effectively
adapt antibiotic use patterns in response to trends in
antibiotic resistance.
On the other hand, there is little difference between
the static- and adaptive-use indices for Acinetobacter. The
similarity between the two indices suggests that there is
little room for clinicians to adapt antibiotic use patterns
to decreasing treatment effectiveness.
DRIs for ﬁrst-line therapy
Clinicians and policymakers may be more concerned
about resistance to ﬁrst-line treatments. Resistance to
these drugs implies the loss of cheaper more widely
used alternatives and could affect drug procurement
budgets if government facilities are an important
source of treatment. Trends in resistance to ﬁrst-line
treatments may also be important for setting national
treatment guidelines, essential drug lists or hospital
formularies.
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Communicating trends in resistance using a drug resistance indexResistance to second-line treatments could indicate
that the need to invest in new antibiotics is more urgent.
The line of treatment DRI is calculated as.
Ri;n line ¼
+
k˛Tn
rt
ikqt
ik
+
k˛Tn
qt
ik
;
where Tn is the set of n-line treatments. From here on,
for simplicity, we report only the adaptive form of the
index for E coli. An important caveat is that when a single
antibiotic corresponds to an entire line of therapy,
the models are equivalent to summarising trends in
resistance to this antibiotic over time.
Over the period 1999e2006, drugs commonly used
as ﬁrst-line therapies for UTIs included, trimetho-
primesulfamethoxazole (TMP-SMX) and ﬂuo-
roquinolones.
6 Results separating antibiotics into
ﬁrst-line and non-ﬁrst-line categories follow for E coli
isolates. The adaptive-use index of resistance to ﬁrst-line
therapies was lower than the resistance to other thera-
pies (ﬁgure 4). However, resistance to ﬁrst-line therapies
increased at a much higher rate, a likely consequence of
their widespread use. Resistance to non-ﬁrst-line thera-
pies remained unchanged over time, suggesting that new
treatment options among these non-ﬁrst-line drugs
preserved their overall effectiveness.
Affordability indices
Antibiotic resistance may force clinicians to use more
expensive antibiotics to treat infections. An affordability
Figure 1 (A) Resistance rates of
Acinetobacter spp. to four
antibiotic classes in the USA,
1999e2006. Note: The following
drugs were used to test for
resistance to antibiotic classes:
third-generation
cephalosporinsdceftriaxone,
ceftazidime;
ﬂuoroquinolonesdciproﬂoxacin,
levoﬂoxacin;
carbapenemsdimipenem; fourth-
generation
cephalosporinsdcefepime.
(B) Resistance rates of
Escherichia coli to eight antibiotic
classes in the USA, 1999e2006.
Note: The following drugs were
used to test for resistance to
antibiotic classes:
aminopenicillinsdampicillin;
trimethoprimesulfamethoxazole;
increased activity
b-lactamsdampicillin/sulbactam,
aztreonam, piperacillin; third-
generation
cephalosporinsdceftriaxone,
ceftazidime; fourth-generation
cephalosporinsdcefepime;
ﬂuoroquinolonesdciproﬂoxacin,
levoﬂoxacin;
aminoglycosidesdgentamicin,
tobramycin;
carbapenemsdimipenem.
Source: author’s calculations
using susceptibility data from The
Surveillance Network .
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Communicating trends in resistance using a drug resistance indexindex summarises resistance trends among cheaper or
more expensive antibiotics. Such an index could mirror
a ﬁrst-line treatment index, but not always. A model of
resistance of an organism to drugs in a certain cost range
may be estimated as follows:
Ri;affordability ¼
+
k
rt
ikqt
ik
+
k
qt
ik
jpriceðkÞ˛C4CALL;
where price(k) is the cost of treatment by drug k and CALL
is the set of costs of treatment for each drug k.
The adaptive DRI for high-cost drugs used to treat E
coli was lower, indicating overall lower levels of resistance
to higher cost drugs (ﬁgure 5). However, there was an
upward trend in the adaptive index for higher cost
drugs, indicating that as resistance increased, there was
a limited set of higher cost drugs that physicians could
prescribe leading to an increasing DRI. Interestingly, the
low-cost adaptive DRI for E coli has remained relatively
ﬂat, consistent with the overall unchanged trend in DRI
for E coli.
Other potential indices
Clinicians do not usually have information on the
infecting organism at start of empiric therapy, but they
do have information on the site of infection. It would
also be possible to set up indices based on the anatom-
ical site and type of infection. Antibiotic use patterns
would be straightforward, but resistance would have to
be weighted against the etiological fraction of the
different causative organisms.
Figure 2 (A) Proportions of
most-common antibiotic classes
used to treat infections caused by
Acinetobacter spp. in the USA,
1999e2006 Source: Author’s
calculations with prescription data
derived from IMS Health Xponent
January 1999 to December 2007,
IMS Health Incorporated. (B)
Proportions of most-common
antibiotic classes used to treat
infections caused by Escherichia
coli in the USA, 1999e2006.
Source: author’s calculations with
prescription data derived from IMS
Health Xponent January 1999 to
December 2007, IMS Health
Incorporated.
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Communicating trends in resistance using a drug resistance indexAnother potential index could contrast the relative
drug effectiveness of gram-positive versus gram-negative
organisms. Similar indices could cover all pathogens in
inpatient versus outpatient settings. Finally, although we
have presented results for antibiotic resistance, similar
indices can be computed for other infectious diseases,
like HIV/AIDS, tuberculosis and malaria, for which
resistance is a problem and the choice of therapeutics
also varies over time.
For all indices discussed so far, subindices can be
computed for different categories and subcategories of
pathogens and then combined to produce the overall
index with weights reﬂecting their shares in the total of
the antibiotics used for treatment.
DISCUSSION
Antibiotic resistance imposes a substantial public health
burden. Quantifying overall changes in resistance over
time and across locations is difﬁcult because resistance of
pathogens to individual drugs must be aggregated to
assess overall burden. Here, we take a ﬁrst step towards the
development of resistance indices, summarising resistance
at the level of the infectious agent.
The results indicate that although clinicians have been
able to adapt to increasing resistance in E coli by
switching to antibiotics that remain active, as indicated
by the divergence between the static-use and adaptive
DRI, they have had fewer alternatives in the case of
Acinetobacter spp., where resistance is increasing to nearly
all agents.
Although we have not presented data by disease
condition, E coli represents the vast majority of UTIs.
Therefore, the DRI for E coli is a useful proxy as a DRI for
UTIs. However, for other pathogens, infections in
different sites of the body represent different challenges
and may not be well represented by a single index. For
instance, pneumococcal infection of the bloodstream or
lungs may be a different challenge than pneumococcal
disease in cerebrospinal ﬂuid, which few drugs pene-
trate. The index should be based on the most recent and
updated clinical breakpoints (S, I and R). These take
Figure 3 Static- and adaptive-
use DRIs for Acinetobacter spp.
and Escherichia coli in the USA,
1999e2006. Note: Dotted lines
represent 95% CIs; CIs for
resistance and use proportion
components derived using
a bootstrap method with m¼1000
simulations. A t test showed that
the difference of means from the
bootstrap distribution was
statistically signiﬁcant at 1% level.
Source: author’s calculations
using susceptibility data from The
Surveillance Network  and
prescription data derived from IMS
Health Xponent January 1999 to
December 2007, IMS Health
Incorporated.
Figure 4 Adaptive DRIs for ﬁrst- and non-ﬁrst-line therapies
for Escherichia coli in the USA, 1999e2006. Note: (A) Dotted
lines represent 95% CIs; CIs for resistance and use proportion
components derived using a bootstrap method with m¼1000
simulations. (B) Trimethoprimesulfamethoxazole and oral
ﬂuoroquinolones used as ﬁrst-line therapies against E coli
urinary tract infections based on Taur and Smith.
6 Source:
author’s calculations using susceptibility data from The
Surveillance Network  and prescription data derived from IMS
Health Xponent January 1999 to December 2007, IMS Health
Incorporated.
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Communicating trends in resistance using a drug resistance indexinto account the clinical effectiveness of a drug for
a given infection. Clinical resistance in this context is
determined by a careful analysis of all available data by
international committees such as the Clinical Laboratory
Standards Institute (formerly NCCLS) in the USA and
the European Committee on Antimicrobial Susceptibility
Testing. Thereby, the success of a given drug is deﬁned
by
i the bacterium’s susceptibility to the drug and by its
pharmacology with regard to the time course of the drug
concentration in the human body (pharmacokinetics)
and the biological effect of the drug at these concentra-
tions on the bacteria (pharmacodynamics), and whenever
available, by information on clinical outcomes.
Ultimately, the robustness of the resistance index will
depend on the quality of surveillance systems that
generate the underlying data on susceptibility and anti-
biotic use. Laboratory capacity remains inadequate in
many parts of the world, although surprisingly large
amounts of quality data are generated but remain
underutilised due to the lack of dedicated surveillance
systems. Susceptibility data are more likely to be reported
from largely tertiary care facilities, where problems of
resistance tend to be greater than in smaller regional
hospitals and could also vary by time of specimen collec-
tion.
7 Thus, trends are likely to be more accurate than
absolute levels. However, data-related challenges are not
unique to resistance; they confront government agencies
charged with computing the consumer price index as
well. DRIs could motivate better reporting of resistance
data from smaller facilities and provide an impetus to
surveillance in both developed and developing countries.
National and regional data on antibiotic sales are
increasingly available through companies like IMS
Health, although in some countries, hospital prescrip-
tions are not included. Gathering accurate data on
antibiotic sales is particularly challenging in countries
with a large informal pharmaceutical sector. Here, sales
from the formal sector may be indicative of trends and
likely mirror sales in the informal sector. A feasible
immediate application of DRIs may be at the scale of the
hospital, where data on both resistance and antibiotic
use are likely to be available.
The resistance index takes a ﬁrst important step towards
making trends in resistance intelligible to non-experts
and useful to experts. Policymakers, particularly in
developing countries, are interested in the implications of
any public health intervention for morbidity, mortality
and current and future drug procurement budgets. We
need to translate susceptibility into metrics that policy-
makers can understand and care about. A further step
would be to tie the resistance index to estimates of actual
disease burden. For instance, how important is resistance
to Acinetobacter, which typically causes fewer infections or
deaths than E coli? Translating the DRI into disease
burden requires a careful unbiased assessment of clinical
outcomes of resistant infections, but in the absence of
these data, morbidity and mortality rates of untreated
infections may well sufﬁce. Correlation between resistance
levels and severity of infection does not imply that the
direction of causality runs from resistance to poor
outcomes. These and other methodological challenges
should be the subject of future efforts.
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